Clinical Data

> A new treatment for advanced and end-stage glaucoma

Primary angle glaucoma, primary angle closure glaucoma, pseudo-exfoliation, neovascular glaucoma, glaucoma associated with steroid uses, uveitis and after keratoplasty surgery(1)


> A very efficient non thermal procedure leading to a reduction in the medication regimen

Significant and persistent reduction in IOP at 9 months(1)

30 % decrease from baseline and less than 21 mmHg

Mean number of medication(1)

  • Before treatment: 3,4 ± 1,7
  • After treatment: 2,9 ± 1,6

> SubCyclo® preserves the structures of the ciliary body (no destructive effects) and improves the uveoscleral drainage

After treatment:

  • No anatomical damage or visible lesion have been observed by ultrasound biomicroscopy(1)
  • UBM shows a thin space between sclera and ciliary body which may correspond to the presence of suprachoroidal fluid[mfn](1)[/mfn]

Image courtesy of Dr. Nassima Benhatchi

> SubCyclo® avoids the side effects of the thermal cyclophotocoagulation procedure

No serious side effects such as intraocular inflammation after treatment(1)
No severe complications such as phthisis bulbi, persistent hypotony, or cystoid macular edema(1)


> A repeatable treatment(1)


> A safe treatment potentially allowing for earlier laser interventions


SubCyclo - A new perspective in Glaucoma Treatment

Yves Lachkar, MD
Nassima Benhatchi, MD

SubCyclo: A new treatment option for advanced and refractory glaucoma

Pieter Gouws, MD

How to enhance SubCyclo laser therapy thanks to the transillumination technique?
Francesco Oddone, MD

A new perspective in the treatment of glaucoma
Lyle Newball, MD

SubCyclo: A new treatment option for advanced and refractory glaucoma?

Pieter Gouws, MD

SubCyclo: A New Treatment Option for Advanced and Refractory Glaucoma
Origins of surgical glaucoma treatment date back to the mid 1800s when iridectomy was discovered as an effective surgical method for the treatment of acute glaucoma and sclerotomy was presented as a procedure for chronic glaucoma.
By Pieter Gouws, MD

READ
Subcyclo laser procedure results in patients with glaucoma
Transscleral cyclophotocoagulation uses a continuous diode laser and it has been a treatment option in advanced glaucoma cases with suboptimal IOP control.
By Romanian Society of Ophthalmology
READ
Significant Improvements for IOP Reduction Seen in SubCyclo
As a leading cause of irreversible blindness worldwide, glaucoma affects around 60.5 million people globally. Significant changes in diagnostic criteria, new therapies, and new tools for glaucoma management techniques have benefited individual patients.
By Robert Noecker, MD
READ

 

Benefits of SubCyclo Laser Therapy Guided by High-frequency Ultrasound Biomicroscopy in Patients With Refractory Glaucoma
To evaluate the efficacy and safety of SubLiminal cyclophotocoagulation using a 25% duty cycle diode laser (Supra 810, SubCyclo, Quantel Medical material and methods).
By Nassima Benhatchi, Djawed Bensmail, Yves Lachkar, MDs
READ

 

Comparative Effectiveness and Tolerance of Subliminal Subthreshold Transscleral Cyclophotocoagulation With a Duty Factor of 25% Versus 31.3% for Advanced Glaucoma
The aim of this study is to compare the effectiveness and the tolerance of subliminal subthreshold transscleral cyclophotocoagulation (SS-TSCPC) with a duty cycle of 25% versus 31.3% with Supra 810nm Subliminal Quantel Medical laser stimulation for advanced glaucoma.
By Nassima Benhatchi, MD
READ

 

SubLiminal Cyclophotocoagulation: A New Perspective
Glaucoma is a leading cause of irreversible blindness affecting approximately 60 million people globally 40 years of age and older.1 Glaucoma is a disease that cannot be ignored, and the need for significant changes in how we diagnose, manage, and treat must be examined and applied whenever possible.
By Lyle Newball, MD
READ

 

(1) – Efficacy, tolerability, side effects, anatomical effects (UBM) of SubCyclo® subthreshold cyclophotocoagulation. 9-month study (43 eyes / 34 patients) presented at the French Society of Ophthalmology 2017 (SFO). Dr. Yves Lachkar and Dr. Nassima Benhatchi – Glaucoma Institute, Saint Joseph Hospital, Paris (France). Data on file

MORE INFORMATION:

Introduction to SubCyclo Treatment Guidelines